Huple movement and coordination development tool

Projektinformationen

HUPLE

ID Finanzhilfevereinbarung: 887303

DOI

10.3030/887303

Projekt abgeschlossen

EK-Unterschriftsdatum 15 November 2019

Startdatum 1 Dezember 2019

Enddatum 31 Mai 2020

Finanziert unter

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Gesamtkosten

€ 71 429,00

EU-Beitrag

€ 50 000,00

Koordiniert durch

HUPLE TRADE SZOLGALTATO KFT
Hungary

Periodic Reporting for period 1 - HUPLE (Huple movement and coordination development tool)

Berichtszeitraum: 2019-12-01 bis 2020-05-31

Zusammenfassung vom Kontext und den Gesamtzielen des Projekts

Children who are born with a disability or become disabled at an early age have to live their whole life in a disadvantaged form and will be restricted from living their life freely and equally, unless they are rehabilitated. Effective rehabilitation procedures and therapies have been reported for children with cerebral palsy (CP). HUPLE provides early intervention and complex therapy for children with movement disorders, mostly resulting from birth injuries – and also to help healthy children improve their balance and coordination ability. It has already been used on 75,000 children with more than 50% of them successfully rehabilitated.
HUPLE is a patented (EU & US) hemisphere shaped balance swing that helps the development of dynamic stability of the head-trunk-pelvis unit through isolated and complex vestibular stimulation. It is used as rehabilitation tool for children with movement disorders and as a development tool for healthy new-borns, children and adults. It incorporates decades of knowledge and experience of improving dynamic stability handicapped children.

Arbeit, die ab Beginn des Projekts bis zum Ende des durch den Bericht erfassten Berichtszeitraums geleistet wurde, und die wichtigsten bis dahin erzielten Ergebnisse

There is a lot of interest from therapy and rehabilitation centres across Europe who already use HUPLE and are demanding larger quantities with enhancements to improve the effectiveness of the therapy. The aim of the Phase 1 feasibility study was to identify a suitable business model that allows the manufacturing of HUPLE to become scalable in order to satisfy market demand and to create a corresponding business and commercialisation plan for the sensor-enhanced HUPLE product based on updated market analysis and customer need. We carried out a technological and economic feasibility study in order to evaluate the full potential of our development. To enter the market, investment will be required for the upgraded HUPLE® production line, building a software support network, manufacturing the first batch with the new production method, and for relevant marketing activities. We have validated the business model in comparative analysis, built partnerships with companies and associations to support our development, and drafted workplan for product development. Based on the positive outcomes we will continue the development.

Fortschritte, die über den aktuellen Stand der Technik hinausgehen und voraussichtliche potenzielle Auswirkungen (einschließlich der bis dato erzielten sozioökonomischen Auswirkungen und weiter gefassten gesellschaftlichen Auswirkungen des Projekts)

Our recent work focused on using 3D orientation sensors attached to HUPLE and using AI-based analytical, predictive and other therapy support software elements with corresponding hardware applications to make the assessment more reliable and to make it more acceptable and likeable by children through special games. Having carried out a thorough market analysis we could state that HUPLE® is a unique diagnostic and therapy device which has no competitor in the world. None of the therapy devices being on the market dispose of the overall capacities of HUPLE®. Its therapeutic effects include the initiation of sensorial sensations and motor functions, the development of cognitive abilities, eye-hand coordination and space orientation, and the positive reinforcement of psychological attitudes. It is an efficient, comfortable, and safe development tool offering more successful therapy.
The novel production method designed will be a huge improvement from the smaller scale technology used presently. The retail tier of our commercialisation strategy will help to reach potential customers and share promotion efforts more effectively. In the current short-term forecast, HUPLE® is estimated to improve the life of around 300,000 children, so social impact is seen to be significant.

logo.jpg